This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Medarex Inc., Ono Pharmaceutical Co., Ltd.. Active years: 2012-2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 152 
1 out of 575 Years Active: 2012-2013
Title: Alasdair Fraser Bell: Innovator in Monoclonal Antibodies
Introduction
Alasdair Fraser Bell is a notable inventor based in Mountain View, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 2 patents, his work has the potential to impact various medical treatments.
Latest Patents
Bell's latest patents include groundbreaking innovations in monoclonal antibodies. One of his patents focuses on monoclonal antibodies against stromal derived factor-1 (SDF-1). This patent provides isolated human monoclonal antibodies that specifically bind to SDF-1 with high affinity. It also includes nucleic acid molecules encoding SDF-1 antibodies, expression vectors, host cells, and methods for expressing these antibodies. Additionally, it discusses immunoconjugates, bispecific molecules, and pharmaceutical compositions that comprise the SDF-1 antibodies. The patent outlines methods for detecting SDF-1 and treating various B cell malignancies, including breast cancer, multiple myeloma, non-Hodgkin's lymphoma, and autoimmune disorders.
Another significant patent by Bell involves CD19 antibodies. This patent provides isolated human monoclonal antibodies that specifically bind to CD19 with high affinity. Similar to his SDF-1 patent, it includes nucleic acid molecules encoding CD19 antibodies, expression vectors, host cells, and methods for expressing these antibodies. It also discusses immunoconjugates, bispecific molecules, and pharmaceutical compositions that comprise the CD19 antibodies. The patent outlines methods for detecting CD19 and treating various B cell malignancies, including non-Hodgkin's lymphoma.
Career Highlights
Throughout his career, Alasdair Fraser Bell has worked with prominent companies in the biotechnology sector. Notable among these are Medarex Inc. and Ono Pharmaceutical Co., Ltd. His experience in these organizations has contributed to his expertise in the development of innovative therapeutic solutions.
Collaborations
Bell has collaborated with several professionals in his field, including Josephine M Cardarelli and Chetana Rao-Naik. These collaborations have likely enhanced his research and development efforts in monoclonal antibodies.
Conclusion
Alasdair Fraser Bell is a distinguished inventor whose work in monoclonal antibodies has the potential to revolutionize treatments for various B cell
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile